Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.

It’s like “Rituxan all over again,” said CEO Richard Miller, who believes Corvus’ lead candidate could make an impact in both ...

The cyber insurance industry is likely to go mainstream and is a simple cost of doing business. Here are a few options to consider. Read now Corvus Insurance, a company focused on applying artificial ...

NEW YORK--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced that it has agreed to acquire Corvus Insurance Holdings, Inc. for approximately $435 million. Founded in 2017, ...

CRVS shares jumped 208.8% in a month following positive cohort 4 results from a phase I eczema study. Corvus Pharmaceuticals reported deeper and more durable responses with eight-week dosing versus ...

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel mechanism of action that so far ...

Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc CRVS with an Outperform rating and a price target of $7.00. Analysts Jeff Jones and Kyle Yang see relapsed/refractory peripheral T-cell ...

BOSTON--(BUSINESS WIRE)--Corvus Insurance, the leading provider of smart commercial insurance products powered by AI-driven risk data, today announced its Risk Aggregation Platform, a data-powered ...

Corvus Pharmaceuticals announced new interim results from its Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis. The randomized, double-blind, ...